AR and prostate carcinoma: All 3 ARIs are nonsteroidal androgen receptor antagonists; enzalutamide and apalutamide have similar molecular structure with high affinity for the ligand-binding domain of androgen receptors.23 However, darolutamide has a unique molecular structure; its active metabolite inhibits androgen receptor translocation and testosterone-induced downstream effects of DNA activation, prostate cancer cell growth, and survival.24